Product Code: 596200598
What's on the KOL ‘wish list' for the next generation of IPF treatments?
Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them? Clearly there is a lot riding on the results of various pipeline drug trials. Which of the next generation of new drugs holds the most promise? Is combination therapy the way forward? Or will cost be the final deciding (or debilitating) factor?
Both marketed brands - Ofev and Esbriet - are covered in detail, as well as 9 pipeline therapies undergoing mid-stage clinical testing. The report examines today's market, looks at future trends and reveals insight from 12 key opinion leaders (KOLs) in North America and Europe.
KOLs share their thoughts, concerns and hopes for the developing IPF treatment pathway, giving clear insight into the factors they believe are most important now and for the future.
Plus: Order the report and you'll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“I will start by saying that the current drugs are somewhat helpful, but we still have a desperate need for drugs that make people feel better, that have fewer side effects, and that have a more profound impact on patient outcomes than the currently available drugs.” US Key Opinion Leader.
Expert insight into the IPF treatment landscape
Recently Marketed Drugs
- Esbriet (pirfenidone, Roche): Is the high pill burden a real or perceived drawback? What is the biggest benefit over Ofev? Are there any differences between EU and US prescribing habits?
- Ofev (nintedanib; Boehringer Ingelheim): What factor is key to choosing Ofev as a first line therapy? How do KOLs feel about the Phase IV combination trial with Esbriet?
- Lebrikizumab (RG-3637; Roche): How do KOLs view subcutaneous administration? Has the halting of AstraZeneca's IL-13 inhibitor Phase II trial made a difference to KOL sentiment?
- Dectrekumab (QAX-576; Novartis): How does this anti-IL-13 antibody compare to lebrikizumab? Is the trial focused on the right patient group?
- SAR156597 (Sanofi): KOLs have split opinions on this drug: why? Where do KOLs expect to see SAR156597 in the treatment algorithm?
- PBI 4050 (ProMetic Life Sciences): Why are KOLs enthusiastic about this newcomer? What concerns are causing the most unease?
- STX-100 (Biogen): How do KOLs rate the drug's mechanism of action? When do physicians think this drug could be used to best effect?
- BMS-986020 (Bristol-Myers Squibb): Interesting in theory only, or showing real promise? Find out what KOLs are saying.
- Pamrevlumab (FG-3019, FibroGen): What do KOLs think about targeting a single cytokine as an approach? Is the potential benefit promising enough to get excited about?
- PRM-151 (Promedior): How much enthusiasm is there regarding PEM-151's novel MOA? Is it being viewed as a monotherapy or an add-on?
- TD-139 (Galecto Biotech): What perceived advantages are already being identified? Are KOLs viewing the dry-powder formulation as a positive or negative?
- Cost is an underlying concern: Both marketed products are expensive and gaining access is challenging for some patients. How will cost impact future prescribing habits? What happens if combination therapies see good trial results? How will payers manage this?
- Patient preference is a key driver: With KOLs seeing no real differences in efficacy between the two marketed products, tolerability become a deciding factor. What concerns do KOLs have about patient response to combination therapies?
- Ongoing debate regarding trials: Who is seen as a Phase II front-runner and why? What expectations do KOLs have of the Ofev/Esbriet Phase IV trial? Why is combination therapy becoming such a focus of attention?
- Change will be gradual: KOLs know not to expect significant change soon, but which outcomes are most eagerly awaited? Faced with potential combination therapies, new mechanisms of action, better diagnostics and improved safety, what is most prized in the long-term?
- Issues with diagnosis: KOLs agree on the benefits of earlier diagnosis but are frustrated - why? Targeting specific patient population segments is desirable but what reasons are given as to why this might be difficult? What new trend did KOLs identify will improve accuracy?
Key Opinion Leaders Interviewed for This Report
KOLs from North America
- Dr. Fernando J. Martinez, MD, MS, Adjunct Professor, Department of Internal Medicine, Division of Pulmonary & Critical Care Medicine, Univ. of Michigan.
- Dr. Joseph A. Lasky, MD, Tenured Professor of Medicine and the Pulmonary/Critical Care Section Chief at Tulane University Medical School.
- Prof. Steven D. Nathan, MD, Medical Director of Inova's Advanced Lung Disease and Transplant Program.
- Dr. Paul Wolters, MD, Associate Professor at the School of Medicine, University of California in San Francisco.
- Dr. Timothy Blackwell, MD, Professor of Medicine (Allergy, Pulmonary, and Critical Care), Professor of Cancer Biology, and Professor of Cell and Developmental Biology, Director of the Division of Allergy, Pulmonary and Critical Care in the Department of Medicine Vanderbilt University Medical Centre in Nashville.
- Dr. Mark Steele, MD, Professor of Medicine in the Department of Allergy, Pulmonary, and Critical Care Medicine at the Vanderbilt University Medical Centre in Nashville.
KOLs from Europe
- Prof. Alessandro Zamparelli, Director of the Unit of Respiratory Diseases, School of Medicine, University of Naples.
- Prof. Carlo Vancheri, Professor of Respiratory Medicine at the University of Catania, Sicily, Italy, Director of the Regional Centre for Rare Lung Diseases and the Laboratory of Experimental Respiratory Medicine.
- Dr. Maria Molina MD, PhD, head of the ILD Unit at Pulmonology Department, Bellvitge University Hospital and the UB-IDIBELL Experimental Pneumology Laboratory.
- Dr. Javier Milara Payá, Senior Researcher, Doctor of Pulmonology and Pharmacy at the University General Hospital in Valencia.
- Two anonymous German KOLs